3 results
PrimaryTo compare progression-free survival (PFS) between tivozanib in combination with mFOLFOX6 and bevacizumab in combination withmFOLFOX6 based on investigator radiological tumor assessmentSecondary• Progression Free Survival (PFS) based on…
Primary Objectives:• To determine the Recommended Dose of Expanion or the MTD for MP0317 as monotherapy in patients with advanced solid tumors (dose-escalation part only)• To characterize the safety and tolerability of MP0317 as monotherapy in…
To prospectively assess whether post-operative adjuvant therapy with pembrolizumab improves recurrence-free survival (RFS) as compared to placebo in high-risk patients with complete resection of Stage IIIA (> 1 mm metastasis), IIIB and IIIC…